The infusion therapy Imaavy (nipocalimab) is now approved in the U.K. for treating people ages 12 and older with generalized myasthenia gravis (MG). The new authorization by the Medicines and Healthcare Products Regulatory Agency (MHRA), the body that regulates the use of medications in Great Britain, allows the…
News
For most people with mild, stable myasthenia gravis (MG), taking a low dose of trazodone hydrochloride, an oral antidepressant also commonly used as a sleep aid, can help ease insomnia —difficulty falling asleep, staying asleep, or waking up too early — without worsening MG symptoms or causing breathing…
News
by Patricia Inacio, PhD
Seronegative MG more rare than previously thought: Danish study
People with myasthenia gravis (MG) who lack detectable MG-related antibodies, known as seronegative MG, may be rarer than previously suggested, according to a single-center study in Denmark. Researchers identified seronegative MG in only 4.3% of 350 cases — a percentage lower than the roughly 10% reported in earlier studies.
The Muscular Dystrophy Association (MDA) is hosting a series of four free, in-person educational events across the U.S. to support families affected by neuromuscular diseases, including myasthenia gravis (MG). Part of the 2026 MDA Engage Symposium series, these upcoming gatherings will connect attendees directly with medical experts, the…
Treatments that suppress or alter immune system activity may help some children and adolescents with juvenile myasthenia gravis (JMG), but more studies are needed to help define the potential benefits and determine best practices. That’s according to a meta-analysis of published studies reporting outcomes of JMG patients who were…
June is Myasthenia Gravis Awareness Month, and advocates around the world are planning a range of events to raise awareness of myasthenia gravis (MG). “MG community members, including patients, care partners, and healthcare providers, host advocacy activities in June each year to promote a broader global understanding of the…
Treatment with Vyvgart (efgartigimod) was associated with rapid and sustained symptom easing, lower corticosteroid use, and no unexpected safety concerns in a small real-world study of adults with generalized myasthenia gravis (gMG). The findings suggest the therapy may be a useful option in individualized treatment plans, although larger,…
Top-line results from a global, late-stage clinical trial testing the experimental cell therapy Descartes-08 against a placebo in adults with generalized myasthenia gravis (gMG) are expected in the first months of 2027. The Phase 3 study, AURORA (NCT06799247), aims to enroll about 100 adults with gMG who test…
More than half of myasthenia gravis (MG) patients with bulbar symptoms, or difficulties swallowing, chewing, and/or speaking, experience a disease exacerbation shortly after starting corticosteroid treatment, according to a study in China. The risk for early exacerbation, or sudden symptom worsening, was found to be significantly higher among patients…
People with myasthenia gravis (MG) tend to have fewer hospitalizations and less need for corticosteroids after starting treatment with Rystiggo (rozanolixizumab-noli), according to an analysis of insurance claims data from the U.S. Corticosteroids are anti-inflammatory medications commonly used in MG, “but long-term use is associated with a…
Recent Posts
- MDA Engage: Seminar connects neuromuscular community in Hershey
- Small wins are big ones when living with myasthenia gravis
- Off-label therapy rapidly eases gMG symptoms, cuts corticosteroid use
- MG changed my relationship with God, and then changed it back
- What July can teach those of us with MG about looking forward